slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 40,801-40,830
Pages 2,019
Rows per page 30
Component
40,801-40,830 of 60,557
20
The slide demonstrates bio-equivalence in binding affinity to a specific T-cell population.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
28
The slide uses a comparison table to establish competitive positioning.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
30
The slide uses a table-like layout to represent a drug development pipeline.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
32
The slide uses a checkmark matrix to highlight the superiority of SPY002.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
33
The slide uses a Y-shaped antibody diagram to annotate specific technical improvements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
40
The chart uses a waterfall-style logic to show the additive effect of the combination therapy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
41
The slide uses donut charts to represent remission rates and highlights the safety advantages of gut-selective backbones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
48
The slide uses a table-based timeline structure to map specific drug candidates (SPY001-004) to expected regulatory and clinical milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
49
The chart uses a custom range bar (min/max) with markers for IPO and Today's market cap.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
50
The slide uses a timeline-based comparison to suggest that Spyre's assets are on a similar trajectory to high-value acquired assets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
05
Includes footnotes regarding arbitration and product definitions.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
06
The table includes a blue box highlighting the Q2 2023 column. Footnotes explain the impact of an arbitration settlement on Manufacturing & Royalty Revenue.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
07
Includes a disclaimer regarding the separation of the oncology business and a footnote about non-GAAP reconciliation.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
15
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Appendix1 hit
16
The table includes specific line items for share-based compensation, depreciation, amortization, separation expenses, tax effects, non-cash interest, and a significant Janssen arbitration award.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Appendix1 hit
08
The table displays mean (SD) or n (%) for various clinical metrics including age, gender, diagnosis duration, and disease activity scores.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a Kaplan-Meier plot to demonstrate clinical efficacy.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
11
The table includes hazard ratios, p-values, and mean changes from baseline for CIDP disease progression and functional scores.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
12
The slide presents clinical trial safety data for VYVGART Hytrulo.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a waterfall chart to bridge EBITDA performance and a table to bridge to EBT.Aston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Satisfaction1 hit
17
The waterfall chart illustrates the bridge between opening and closing cash balances.Aston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Satisfaction1 hit
18
The slide includes a footnote regarding rounding and exchange rates.Aston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Satisfaction1 hit
22
Includes a table of financial metrics, two donut charts showing shareholder composition, and a bar chart showing net leverage ratio.Aston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations 1 hit
03
AstraZeneca | Results Presentation Deck | 44 slidesAstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit
10
The slide uses a standard financial reporting format for a pharmaceutical company.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
11
The slide includes a navigation bar at the top and a footer with definitions and disclaimers.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
18
The slide uses a matrix-like structure to categorize trials by cancer type and development strategy (monotherapy vs. combinations vs. biomarker assessment).AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
23
The slide uses a horizontal navigation bar at the top to indicate the current section of the presentation.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations 1 hit
29
The slide uses a three-column layout to categorize decarbonization efforts into specific scopes and programs.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
36
The slide uses a grid layout to categorize clinical trials (e.g., DESTINY-Breast, CAPItello) by patient population and treatment line.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations 1 hit